

1 **Conclusion:** The subgroups of patients treated with hydroxychloroquine and/or
2 favipiravir did not have similar disease severities in our study. Therefore, further studies
3 with homogeneous patient groups to be arranged prospectively are needed.

4 **Key words:** COVID-19, hydroxychloroquine, favipiravir, outpatients, treatment

5 **1. Introduction**

6 The coronavirus disease 2019 (COVID-19) pandemic is the biggest health threat to
7 humanity after the 1918 influenza pandemic. Since its first detection in December 2019,
8 COVID-19 has affected nearly 75 million people in a year, and more than 1.5 million
9 people have died due to SARS-CoV-2. SARS-CoV-2 virus causes COVID-19 disease
10 and severe acute respiratory syndrome. The disease is characterized by flu-like
11 symptoms. Some patients are asymptomatic, pulmonary involvement often develop in
12 symptomatic patients and progressive disease can be life threatening*.

13 There is no specific drug to treat COVID-19. Since the beginning of the pandemic,
14 many drugs such as favipiravir, remdesivir, hydroxychloroquine, lopinavir / ritonavir
15 have been used in the treatment of the disease. Chloroquine is a classic antimalarial
16 drug and also has anti-inflammatory and immunomodulatory effects in viral infections.
17 Hydroxychloroquine is a chloroquine metabolite and is less toxic. Chloroquine and
18 hydroxychloroquine have been demonstrated to inhibit SARS-CoV-2 in vitro, but their
19 clinical efficacy and benefits are not yet known. Favipiravir is a nucleotide analogue
20 approved in China and Japan for the treatment of influenza. Favipiravir prevents the
21 replication of the RNA virus by selectively inhibiting RNA-dependent RNA
22 polymerase. Since the RNA-dependent RNA polymerase gene of SARS-CoV-2 is
23 similar to influenza viruses, it has also been proposed in the treatment of COVID-19
24 [1]. Hydroxychloroquine and favipiravir have been used alone or in combination in the

1 treatment of COVID-19 since the beginning of the pandemic in Turkey. In this study,
2 we aimed to investigate the effects of hydroxychloroquine and favipiravir on the clinical
3 course in COVID-19 outpatients receiving early treatment.

4 *World Health Organisation (2020). Novel coronavirus-2019. Website
5 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019> [Accessed
6 15.12.2020]

7 **2. Materials and methods**

8 The study was carried out in the hospitals located in İzmir, Turkey. This observational
9 retrospective study was approved by the Clinical Research Ethics Committee of İzmir
10 Katip Çelebi Üniversitesi, Institutional Review Board. Data were collected from August
11 1st to November 30th from all outpatients diagnosed with definitive COVID-19 and
12 receiving treatment. Reverse transcriptase polymerase chain reaction (RT-PCR) test was
13 applied to all outpatients meeting the definition of the possible case definition according
14 to The Republic of Turkey Ministry of Health COVID-19 guideline**. PCR sampling
15 frequency was a part of the routine follow-up process. Patients with PCR-documented
16 SARS-CoV-2 RNA from nasopharyngeal samples were prescribed hydroxychloroquine
17 (200 mg twice daily for 5 days) and favipiravir (two 1600 mg oral loading doses on day
18 1, followed by 600 mg twice daily on days 2-5) as early treatment, whether or not they
19 had symptoms. Serum electrolyte analysis and electrocardiogram were evaluated before
20 the treatment.

21 Public Health Management System (Halk Sağlığı Yönetim Sistemi-HSYS) was used for
22 the case-based follow-up. Patients who received antiviral treatment for at least five days
23 and patients who were followed-up for 30 days were included in this analysis. All PCR-
24 positive COVID-19 outpatients whose data could be accessed during the study period

1 were included in the study. A total of 468 PCR-positive outpatients were excluded from
2 the study due to being under 18 years of age, previous COVID-19 diagnosis, pregnancy
3 and missing data. PCR samplings were repeated on the 1st, 3th and 14th days.
4 Symptoms were evaluated on the 1st, 3th, 5th, 14th and 30th days of follow-up.
5 Demographics and laboratory results on the day of admission were recorded. COVID-
6 19 pneumonia was confirmed by thoracic computed tomography (CT). The clinical data
7 (symptoms, antiviral-related side effects, requirement for hospitalization, recovery) of
8 these outpatients who were followed up by telephone or personal visits were evaluated
9 retrospectively. The treatment was decided by the filiation teams according to the age
10 and comorbid status of the outpatients. Patients were divided into three groups
11 according to the treatment they received such as hydroxychloroquine, favipiravir and
12 both hydroxychloroquine + favipiravir. The primary outcomes were symptom
13 improvement, PCR negativity and need for hospitalization. The effects of
14 hydroxychloroquine and favipiravir on the clinical course were evaluated statistically.
15 Statistical calculations were performed using SPSS (Statistical Package for the Social
16 Science; IBM Corp, Armonk, NY, USA), version 26. Categorical variables between
17 groups were compared with the chi-square test and confidence interval. ANOVA F test
18 or Student-t test was used for the analysis of continuous variables, where appropriate.
19 Logistic regression analysis was performed to explore which factors were predictive for
20 clinical course. Significant variables at $p < 0.05$ in univariate analyses were introduced
21 in the initial multivariate model. A stepwise approach was applied to evaluate the
22 iteration of variables and to control potential confounders. A p value less than 0.05 was
23 considered statistically significant.

1 ** T.C. Sağlık Bakanlığı COVID-19 Bilgilendirme Platformu (2020). Website
2 <https://covid19.saglik.gov.tr> [Accessed 15.12.2020]

3 **3. Results**

4 **3.1. Demographic findings**

5 During the study period, a total of 1957 outpatients test results were positive for SARS-
6 CoV-2 RNA. Of these outpatients, 468 of them were excluded from the study due to
7 being under 18 years of age, previous COVID-19 diagnosis, pregnancy and missing
8 data. Finally, we enrolled 1489 outpatients in this study. Overall, 775 (52%) patients
9 were male and the mean age of patients was 38.9 ± 11.1 years. The minority of the
10 patients (11.6%) had at least one comorbid disease including diabetes (10.1%),
11 hypertension (3.2%) and malignancy (0.6%). The proportion of asymptomatic patients
12 was 720 (48.4%), while the number of patients with upper respiratory tract infection
13 was 644 (43.3%) and the number of patients with lower respiratory tract infection was
14 230 (15.4%). Demographic and laboratory findings are presented in Table 1.

15 Of these patients, 537 of them were received favipiravir, 545 of them were received
16 hydroxychloroquine and 407 of them were received both favipiravir and
17 hydroxychloroquine. At least one side-effect attributed to the favipiravir and/or
18 hydroxychloroquine was observed in 17.5% of patients. The side-effects of antiviral
19 treatment were gastrointestinal disturbances (12.1%), allergic reactions (3.5%) and
20 cardiac arrhythmia (1%). No significant difference was observed between patients
21 receiving favipiravir and hydroxychloroquine in terms of side effects ($p=0.086$).

22 **3.2. Effects of antivirals on symptom improvement**

23 The rates of symptoms were similar in symptomatic patients except for the loss of smell
24 and taste on the first day of treatment (Table 1). Cough was less common in the group

1 of patients who received hydroxychloroquine on the 3rd day of treatment ($p=0.029$). In
2 addition, the group that received hydroxychloroquine had a higher rate of recovery from
3 joint pain on the 14th day and myalgia on the 30th day ($p=0.001$ and $p=0.046$). The
4 number of patients whose all symptoms improved on the 14th day of follow-up was
5 higher in the group of patients receiving hydroxychloroquine ($p=0.003$).

6 Logistic regression model was used to examine the independent effects of antivirals on
7 symptom improvement. The antiviral drugs, the presence of comorbidity and
8 pneumonia are included in this model. On the 14th day of follow-up, regardless of the
9 presence of comorbidity and pneumonia, symptom improvement was 1.8 times higher
10 among patients who received hydroxychloroquine compared to patients who received
11 favipiravir (Table 2).

12 **3.3. Effects of antivirals on PCR negativity**

13 On the 3rd day of follow-up, PCR negativity rate was higher in patients receiving
14 hydroxychloroquine ($p=0.004$), but this difference was not significant on the 14th day
15 ($p=0.502$). The presence of pneumonia as a confounding factor was included in the
16 logistic regression model to examine the independent effects of antivirals on PCR
17 negativity at 3rd day of follow-up. Sex, age and comorbidity were not included in this
18 analysis because they were not found to be related with PCR negativity. Accordingly,
19 on the 3rd day of the treatment, it was found that PCR negativity was higher in the
20 asymptomatic patients (Odds ratio [OR]: 1.41, 95% Confidence Interval [CI]: 1.12-
21 1.79), in patients without pneumonia (OR: 1.57, 95% CI: 1.11-2.24) and in patients who
22 received hydroxychloroquine compared to patients received favipiravir (OR: 1.44, 95%
23 CI: 1.09-1.91). Combined antiviral therapy had no effect on PCR negativity on the 3rd
24 day of treatment (Table 3).

1 **3.4. Subgroup analysis of hospitalized patients**

2 All patients included in the study recovered from COVID-19 during the follow-up
3 period. A total of 40 patients were hospitalized; 7 of them had severe pneumonia, 5 of
4 them were followed in Intensive Care Unit (ICU) and only one patient required
5 mechanical ventilation. Hospitalization rates were similar in patients receiving
6 favipiravir and hydroxychloroquine ($p=0.144$) (Table 1).

7 Logistic regression analysis was used for evaluating independent factors affecting
8 hospitalization. The presence of pneumonia was included in the model as an effect
9 modifier. The odds ratio for age indicated that each 1 -year increase in age increased the
10 relative risk of hospitalization by 1.04-fold (Table 4). In the presence of pneumonia at
11 the time of diagnosis, the hospitalization rate was 6.6 times higher in patients who
12 received favipiravir than those who received hydroxychloroquine. In similar, the
13 hospitalization rate was 7.3 times higher in patients who received combined therapy
14 compared with those who received hydroxychloroquine (Table 4).

15 **4. Discussion**

16 Aside from the now, more than 1.8 million Turkish people have been infected with
17 SARS-Cov-2 according to the Republic of Turkey Ministry report**. Although social
18 distancing, staying at home and wearing face masks served to reduce the hospital
19 burdens and spread them over time, these measures only reduced reproduction numbers
20 to about 1.0 [2]. Moreover, considering that isolation policies will be lifted over time, it
21 can be predicted that many people will be exposed to the COVID-19 in the future, even
22 if these social isolation measures are maintained.

23 While the vast majority of COVID-19 patients is at low risk of progression or show the
24 infection without symptoms, for the remaining patients, outpatient treatment is

1 necessary for preventing hospitalization and disease progression. Thus, the way to
2 prevent loss of life and return the society with normal functioning is an effective and
3 safe outpatient treatment [3].

4 Although there is no anti-viral treatment with proven efficacy in the treatment of
5 COVID-19, drugs such as chloroquine/hydroxychloroquine, azithromycin,
6 lopinavir/ritonavir, favipiravir and remdesivir have been used widely.
7 Hydroxychloroquine and favipiravir, which are included in the treatment protocol in
8 many national treatment guidelines, are also used in our country according to The
9 Republic of Turkey Ministry of Health COVID-19 guideline**. There are many studies
10 about these drugs in the literature especially on hospitalized patient groups [4-7]. Early
11 outpatient disease is not the same as a later hospitalization illness, as a result, different
12 treatments affects may be obtained in different patient groups [3]. Due to the limited
13 number of studies with large numbers of outpatients examining early initiation of
14 antiviral therapy, we examined the effects of these drugs, which were initiated in early
15 period, on the clinical course of outpatients.

16 Chloroquine and its derivatives are widely used as immunomodulators in the treatment
17 of rheumatic diseases [8]. As the pharmacological property of chloroquine and its
18 derivatives are studied, additional clinical applications, especially based on its antiviral
19 activity against human coronaviruses are increasingly appreciated [9]. The action of
20 hydroxychloroquine such as antioxidant activities and regulation in proinflammatory
21 cytokines encourages its administration due to the cytokine storm in patients with
22 severe COVID-19 [10]. Therefore, hydroxychloroquine has been used in the treatment
23 with the assumption that it will be a protective agent in SARS-CoV-2 infection with its
24 antiviral and autoimmune regulating effect. While hydroxychloroquine has been found

1 to be effective in the prophylaxis and treatment of COVID-19 in some studies, other
2 studies have claimed otherwise [7,11,12]. In a meta-analysis conducted by Elavarasi et
3 al., there was no significant difference in virologic clearance between placebo and
4 hydroxychloroquine in the meta-analysis of two randomized-controlled trials and three
5 cohort studies [11]. In addition, the time of fever remission, clinical deterioration,
6 development of ARDS and need for mechanical ventilation rates were similar between
7 the hydroxychloroquine arm and standard of care [11]. In a meta-analysis in which four
8 randomized controlled trials were analyzed, the use of hydroxychloroquine for COVID-
9 19 prophylaxis, compared to placebo, did not reduce the risks of developing COVID-19,
10 hospitalization or mortality, however, hydroxychloroquine use increased the risk of
11 adverse events [12]. In our study, hydroxychloroquine was found effective in improving
12 symptoms. We also showed COVID-19 outpatients who received hydroxychloroquine
13 had higher rate of PCR negativity on the 3rd day, but no significance was found in
14 terms of PCR negativity on the 14th day. In addition, the use of hydroxychloroquine
15 was associated with fewer hospitalization rates in COVID-19 outpatients with
16 pneumonia. Our results may be due to the higher rate of asymptomatic or mildly
17 symptomatic patients in the group receiving hydroxychloroquine. Eventually, the fact
18 that the patient groups were not randomly selected prospectively and the absence of a
19 control group make the generalizability of our research findings debatable. In addition,
20 subgroups of patients treated with hydroxychloroquine and/or favipiravir did not have
21 similar disease severities in our study. The higher rate of pneumonia at the time of
22 diagnosis in patients receiving favipiravir may explain the higher rate of hospitalization
23 in this patient group. Therefore, further studies with homogeneous patient groups to be
24 arranged prospectively are needed.

1 Favipiravir, a potent inhibitor of RNA-dependent RNA polymerase, was approved for
2 reemerging pandemic influenza in Japan [13]. Favipiravir has shown in vitro activity
3 against SARS-CoV-2 by reduction in the number of infectious particles and cytopathic
4 effect [14]. There are mostly observational studies evaluating the efficacy of favipiravir
5 in different patient groups, and conflicting results have been obtained in these studies
6 [15,16]. Two randomized, open-label controlled trials are currently underway to
7 evaluate the efficacy of early favipiravir treatment in outpatients with early stage
8 COVID-19 [17,18]. In our study, the parameters used to evaluate clinical course, were
9 yielded more positive outcomes in patients receiving hydroxychloroquine compared to
10 patients receiving favipiravir. The positive effects of early antiviral therapy on the
11 clinical course may be attributed to the anti-inflammatory and immunomodulatory
12 effects rather than the antiviral effect. A possible explanation for the superiority of
13 favipiravir over combination therapy in our study can be attributed to the fact that the
14 number of asymptomatic patients in the patient group receiving favipiravir is higher
15 compared to the patient group receiving combination therapy.

16 Our study has some limitations. The first of these was the absence of a control group
17 that did not receive antiviral treatment. Secondly, since we did not have complete access
18 to the entire number of patients diagnosed during the study period, it is difficult to
19 assess whether our findings were representative of the entire population. Similarly, we
20 could not access any information about the quality control of the data. Another
21 limitation of the study was that the different subgroups of patients treated with different
22 medications had different disease severities and that it is difficult to make comparisons
23 of the effectiveness of these drugs. In addition; observational, retrospective and

1 nonrandomized design of our study restricted the reliability of our findings, even though
2 large number of patients and multicentric design.

3 The antiviral drugs administered in the early phase of infection can shorten the course of
4 the clinical disease and thus may reduce the infectiousness by reducing viral spread.

5 Data of the ongoing randomized controlled trials and meta-analyses will indicate the
6 efficacy of these antivirals in COVID-19 outpatient clearly, so we need to wait for more
7 clinically valid evidence to confirm the value of this antiviral agent for COVID-19
8 treatment.

9 **References**

- 10 1. Dong X, Tian Z, Shen C, Zhao C. An overview of potential therapeutic agents to
11 treat COVID-19. *BioScience Trends* 2020; 4; 14(5): 318-327. doi:
12 10.5582/bst.2020.03345
- 13 2. Xu J, Hussain S, Lu G, Zheng K, Wei S et al. Associations of Stay-at-Home
14 Order and Face-Masking Recommendation with Trends in Daily New Cases and
15 Deaths of Laboratory-Confirmed COVID-19 in the United States. *Exploratory
16 Research and Hypothesis in Medicine* 2020; 1-10. doi:
17 10.14218/ERHM.2020.00045
- 18 3. Risch HA. Early Outpatient Treatment of Symptomatic, High-Risk COVID-19
19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic
20 Crisis. *American Journal of Epidemiology* 2020; 189(11): 1218-1226. doi:
21 10.1093/aje/kwaa093
- 22 4. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL,
23 Staplin N et al. Effect of Hydroxychloroquine in Hospitalized Patients with

- 1 Covid-19. *New England Journal of Medicine* 2020; 383(21): 2030-2040. doi:
2 10.1056/NEJMoa2022926
- 3 5. Yu B, Li C, Chen P, Zhou N, Wang L et al. Low dose of hydroxychloroquine
4 reduces fatality of critically ill patients with COVID-19. *Science China Life*
5 *Sciences* 2020; 63(10): 1515-1521. doi: 10.1007/s11427-020-1732-2
- 6 6. Hong TS, Gonzalez J, Nahass RG, Brunetti L. Impact of Hydroxychloroquine on
7 Mortality in Hospitalized Patients with COVID-19: Systematic Review and
8 Meta-Analysis. *Pharmacy (Basel)* 2020; 8(4): 208. doi:
9 10.3390/pharmacy8040208
- 10 7. Prodromos C, Rumschlag T. Hydroxychloroquine is effective, and consistently
11 so when provided early, for COVID-19: a systematic review. *New Microbes and*
12 *New Infections* 2020; 38: 100776. doi: 10.1016/j.nmni.2020.100776
- 13 8. Chen Z, Hu J, Zhang Z, Jiang S, Han S et al. Efficacy of hydroxychloroquine in
14 patients with COVID-19: results of a randomized clinical trial. *MedRxiv*
15 2020.03.22.20040758. doi: 10.1101/2020.03.22.20040758
- 16 9. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and
17 chloroquine: implications for rheumatology. *Nature Reviews Rheumatology*
18 2020; 16(3): 155-166. doi: 10.1038/s41584-020-0372-x
- 19 10. Liu J, Li S, Liu J, Liang B, Wang X et al. Longitudinal characteristics of
20 lymphocyte responses and cytokine profiles in the peripheral blood of SARS-
21 CoV-2 infected patients. *EBioMedicine* 2020; 55: 102763. doi:
22 10.1016/j.ebiom.2020.102763
- 23 11. Elavarasi A, Prasad M, Seth T, Sahoo RK, Madan K et al. Chloroquine and
24 Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and

- 1 Meta-analysis. *Journal of General Internal Medicine* 2020; 35(11): 3308-3314.
2 doi: 10.1007/s11606-020-06146-w
- 3 12. Lewis K, Chaudhuri D, Alshamsi F, Carayannopoulos L, Dearness K et al;
4 GUIDE Group. The efficacy and safety of hydroxychloroquine for COVID-19
5 prophylaxis: A systematic review and meta-analysis of randomized trials. *PLoS*
6 *One* 2021; 16(1): e0244778. doi: 10.1371/journal.pone.0244778
- 7 13. Joshi S, Parkar J, Ansari A, Vora A, Talwar D et al. Role of favipiravir in the
8 treatment of COVID-19. *International Journal of Infectious Diseases* 2020; 102:
9 501-508. doi: 10.1016/j.ijid.2020.10.069
- 10 14. Shannon A, Selisko B, Le NT, Huchting J, Touret F et al. Rapid incorporation of
11 Favipiravir by the fast and permissive viral RNA polymerase complex results in
12 SARS-CoV-2 lethal mutagenesis. *Nature Communications* 2020; 11(1): 4682.
13 doi: 10.1038/s41467-020-18463-z
- 14 15. Siordia JA Jr, Bernaba M, Yoshino K, Ulhaque A, Kumar S et al. Systematic
15 and Statistical Review of Coronavirus Disease 19 Treatment Trials. *SN*
16 *Comprehensive Clinical Medicine* 2020: 1-12. doi: 10.1007/s42399-020-00399-
17 6
- 18 16. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N et al. Favipiravir
19 versus other antiviral or standard of care for COVID-19 treatment: a rapid
20 systematic review and meta-analysis. *Virology Journal* 2020; 17(1): 141. doi:
21 10.1186/s12985-020-01412-z
- 22 17. Duvignaud A, Lhomme E, Pistone T, Onaisi R, Sitta R et al; COVERAGE study
23 group. Home Treatment of Older People with Symptomatic SARS-CoV-2
24 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-

1 Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and
2 Tolerability of Several Experimental Treatments to Reduce the Risk of
3 Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE
4 trial). *Trials* 2020; 21(1): 846. doi: 10.1186/s13063-020-04619-1

5 18. Hanna CR, Blyth KG, Burley G, Carmichael S, Evans C et al. Glasgow Early
6 Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19:
7 A structured summary of a study protocol for a randomised controlled trial.
8 *Trials* 2020; 21(1): 935. doi: 10.1186/s13063-020-04891-1

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

1 **Table 1.**Demographic, laboratory and follow-up findings of COVID-19 outpatients

	Total (n=1489, 100%)	Favipiravir (n=537, 36.1%)	Favipiravir +hydroxychlo roquine (n=407, 27.3%)	Hydroxychlo roquine (n=545, 36.6%)	p
Male (n, %)	775 (52)	278 (51.8)	210(51.6)	287 (52.7)	0.941
Age (years) (Mean ±SS / Median min- max)	38.9 ±11.1 39 (16-82)	39.7±11.2 40 (18-82)	39 ±10.8 39 (18-77)	37.9±11.1 37 (16-80)	0.021
Comorbidity (n, %)					
At least one underlying disease	172 (11.6)	58 (10.8)	51(12.5)	63 (11.6)	0.723
Diabetes mellitus	150 (10.1)	51 (9.5)	46(11.3)	53 (9.7)	0.617
Hypertension	48 (3.2)	12 (2.2)	16 (3.9)	19 (3.5)	0.293
Malignancy	9(0.6)	1(0.2)	1 (0.7)	5 (0.9)	0.324
Symptoms at the time of diagnosis(n, %)					
Asymptomatic patients	720 (48.4)	269 (50.1)	187 (45.9)	264 (48.4)	0.449

Patients with upper respiratory symptoms	644(43.3)	208(38.7)	195 (47.9)	241(44.2)	0.016
Patients with pneumonia	230 (15.4)	108 (20.1)	53 (13)	69 (12.7)	0.001
Fever	173 (11.6)	56 (10.4)	49 (12)	68 (12.1)	0.551
Cough	253 (17)	99 (18.4)	76 (18.7)	78 (14.3)	0.111
Sore throat	176 (11.2)	62 (11.5)	48 (11.8)	57 (10.5)	0.767
Shortness of breath	89 (6)	24 (4.5)	25 (6.1)	40 (7.3)	0.136
Myalgia	271 (18.2)	106 (19.7)	75 (18.4)	90 (16.5)	0.384
Joint pain	14 (0.9)	0	0	14 (2.6)	-
Loss of smell and taste	157 (10.5)	49(9.1)	58 (14.3)	50 (9.2)	0.017
Diarrhea	66 (4.4)	23 (4.3)	18 (4.4)	25 (4.6)	0.987
Laboratory findings at the time of diagnosis (Mean ±SS / Median min-max)					
White blood cell (cells/mm ³)	5.8 ±1.4 5.6 (1.6-15.2)	5.6 ±1.4 5.6 (1.6-15.2)	5.8 ±1.4 5.7 (3.1-12.6)	5.8 ±1.5 5.6 (2.3-13.3)	0.078

Lymphocyte (cells/mm ³)	2.2 ±4 1.6 (0.3-47.8)	1.9 ±2.5 1.6 (0.3-30.3)	2.2 ±4 1.5 (0.5-41.7)	2.5 ±5 1.7 (0.5-47.8)	0.075
Neutrophil (cells/mm ³)	4.2 ±7 3.3 (0.4-85.7)	4.2 ±7.9 3.2 (0.6-85.7)	4.5 ±7.3 3.4 (0.8-65.1)	4 ±5.7 3.3 (0.4-72)	0.587
Glucose (mg/dL)	102 ±32 96 (52-510)	104 ±36 98 (61-510)	100±28 96 (72-297)	100 ±28 96 (52-395)	0.234
AST (U/L)	28.8 ±21.8 23 (4-268)	29 ±24.8 23 (5-268)	26 ±15 22 (4-111)	30.7 ±23 25 (8-268)	0.024
ALT (U/L)	28 ±14.8 25 (9-214)	28 ±16.2 24 (9-161)	26 ±10.4 24 (11-74)	29.5±16 26 (12-214)	0.010
LDH (U/L)	206 ±68.3 199 (18-447)	211±69 202 (20-429)	203 ±65.1 195 (25-447)	202 ±69 200 (18-374)	0.535
BUN (mg/dL)	26 ±9.5 25.5 (2-65)	26 ±9.5 26 (8-65)	25 ±8.8 25 (2-55)	26.8 ±10 26 (4-58)	0.172
Serum creatinine	0.9±0.19	0.9±0.19	0.9±0.17	0.9±0.19	0.570

(mg/dL)	0.9 (0.1-2.19)	0.9 (0.1-2.19)	0.9 (0.1-1.7)	0.9 (0.1-1.7)	
D-dimer (ng/mL)	295 ±488.6 190 (1-9060)	310 ±576 204 (1-9060)	304 ±444 191 (3-444)	271±393 164 (1-4130)	0.871
Ferritin (ng/mL)	84 ±120.5 39.4 (3-1235)	85 ±116 37 (3-890)	76 ±91 36.9 (3-502)	88 ±144 44.4 (5-1235)	0.606
Procalcitonin (ng/mL)	0.06 ±0.1 0.03 (0.01-1.1)	0.06 ±0.08 0.04 (0.01-0.5)	0.04 ±0.03 0.03 (0.01-0.1)	0.08 ±0.2 0.03 (0.01-1.1)	0.241
CRP (mg/dL)	8.8±15.8 3.7 (0.5-156)	9.2±17 4.1 (0.5-156)	9.7±18.5 3.7 (0.1-135)	7.6±11.8 3.3 (0.1-90)	0.085
3th day of follow-up					
At least one symptom	605 (40.6)	221 (41.2)	169 (41.5)	215 (39.4)	0.778
Fever	78 (5.2)	33 (6.1)	18 (4.4)	27 (5)	0.470
Cough	220 (14.8)	90 (16.8)	67 (16.5)	63 (11.6)	0.029

Sore throat	103 (6.9)	45 (8.4)	23 (5.7)	35 (6.4)	0.225
Shortness of breath	74 (5)	21 (3.9)	22 (5.4)	31 (5.7)	0.369
Myalgia	179 (12)	70 (13)	51 (12.5)	58 (10.6)	0.444
Joint pain	10 (0.7)	1 (0.2)	0	9 (1.7)	
Loss of smell and taste	169 (11.3)	57 (10.6)	44 (10.8)	68 (12.5)	0.582
Diarrhea	43 (2.9)	14 (2.6)	9 (2.2)	20 (3.7)	0.385
PCR positivity	(1213)	(432)	(322)	(459)	
	454 (37.4)	169 (39.1)	139 (43.2)	146(31.8)	0.004
5th day of follow-up					
At least one symptom	442 (29.7)	160 (29.8)	124 (30.5)	158 (29)	0.884
Fever	49 (3.2)	21 (3.9)	6 (1.5)	22 (4)	0.056
Cough	183 (12.3)	72 (13.4)	55 (13.5)	56 (10.3)	0.204
Sore throat	74 (5)	30 (5.6)	12 (2.9)	32 (5.9)	0.088
Shortness of breath	58 (3.9)	20 (3.7)	21(5.2)	17 (3.1)	0.267
Myalgia	137 (9.2)	54 (10.1)	41(10.1)	42 (7.7)	0.321
Joint pain	0	0	0	0	

Loss of smell and taste	116 (7.8)	40 (7.4)	33 (8.1)	43 (7.9)	0.925
Diarrhea	26 (1.7)	11 (2)	4 (1)	11 (2)	0.404
14th day of follow-up					
At least one symptom	239 (16.1)	105 (19.6)	68 (16.7)	66(12.1)	0.003
Fever	25 (1.7)	10 (1.9)	7 (1.7)	8 (1.5)	0.876
Cough	91 (6.1)	44 (8.2)	23 (5.7)	24 (4.4)	0.031
Sore throat	33 (2.2)	18 (3.4)	6 (1.5)	9 (1.7)	0.083
Shortness of breath	30 (2)	13 (2.4)	10 (2.5)	7 (1.3)	0.333
Myalgia	63 (4.2)	31 (5.8)	15 (3.7)	17 (3.1)	0.076
Joint pain	34 (2.3)	23 (4.3)	6 (1.5)	5 (0.9)	0.001
Loss of smell and taste	59 (4)	24 (4.5)	17(4.2)	18 (3.3)	0.599
Diarrhea	8 (0.5)	4 (0.7)	2 (0.5)	2 (0.4)	0.684
PCR positivity	(1105)	(389)	(298)	(418)	0.502
	35 (3.2)	9 (2.3)	11 (3.7)	15 (3.6)	
30th day of follow-up					

At least one symptom	180 (12.1)	70 (13)	61 (15)	49 (9)	0.014
Fever	26 (1.7)	12 (2.2)	10 (2.5)	4 (0.7)	0.059
Cough	56 (3.8)	21 (3.9)	21 (5.2)	14 (2.6)	0.115
Sore throat	22 (1.5)	8 (1.5)	7 (1.7)	7 (1.3)	0.830
Shortness of breath	26 (1.7)	9 (1.7)	11 (2.7)	6 (1.1)	0.180
Myalgia	57 (3.8)	29 (5.4)	14 (3.4)	14 (2.6)	0.046
Joint pain	37 (2.5)	12 (2.2)	11 (2.7)	14 (2.6)	0.913
Loss of smell and taste	38 (2.6)	15 (2.8)	15 (3.7)	8 (1.5)	0.088
Diarrhea	4 (0.3)	1 (0.2)	2 (0.5)	1 (0.2)	0.685

1 *BUN: Blood urea nitrogen, AST: Aspartateaminotransferase, ALT: Alanine
2 aminotransferase, LDH: Lactate dehydrogenase, CRP: C-reactive protein, PCR:
3 Polymerase chain reaction

4
5
6
7
8

1 **Table 2.** Factors Affecting Symptom improvement in symptomatic outpatients on the
 2 14th day of follow-up (n=877)

Risk Factors	OR_{adj} (95% Confidence Interval)	p
Absence of comorbidity	1.9 (1.0-3.5)	0.054
Absence of pneumonia	1.4 (0.9-2.1)	0.145
Antiviral treatment		
Hydroxychloroquine	1.8 (1.2-2.7)	0.005
Hydroxychloroquine + Favipiravir	1.1 (0.7-1.7)	0.622
Favipiravir (Ref)	1	

3

4

5

6

7

8

9

10

1 **Table 3.**Factors Affecting PCR negativity on the 3th day of follow-up (n=1489)

Risk Factors	OR_{adj} (95% Confidence Interval)	p
Lack of symptoms	1,41 (1,12-1,79)	0,004
Absence of pneumonia	1,57 (1,11-2,24)	0,012
Antiviral treatment		
Hydroxychloroquine	1,44 (1,09-1,91)	0,010
Hydroxychloroquine + Favipiravir	0,89 (0,66-1,19)	1,424
Favipiravir (Ref)	1	

2

3

4

5

6

7

8

9

1 **Table 4.**Factors affecting hospitalization of COVID-19 outpatients (n=1489)

Risk Factors	OR_{adj} (95% Confidence Interval)	p
Age (years)	1.04 (1.01-1.07)	0.018
Presence of comorbidity	1.4 (0.6-3.2)	0.436
Presence of any symptoms	4.6 (2.0-10.7)	<0.001
Antiviral treatment		
Favipiravir	0.8 (0.3-2.2)	0.669
Hydroxychloroquine + Favipiravir	0.7 (0.3-2.2)	0.565
Hydroxychloroquine	Ref	
Antiviral treatment in outpatients with pneumonia		
Favipiravir	6.6 (2.4-18.4)	<0.001
Hydroxychloroquine + Favipiravir	7.3 (2.0-26.9)	0.003
Hydroxychloroquine	Ref	

2

3